Novo Nordisk Announces Headline Results From The FRONTIER 2 Trial; Achieved Its Co-Primary Endpoints By Demonstrating A Reduction Of Treated Bleeding Episodes With Both Once-Weekly And Once-Monthly Mim8 Versus No Prophylaxis Treatment And Prior...
Novo Nordisk Announces Headline Results From The FRONTIER 2 Trial; Achieved Its Co-Primary Endpoints By Demonstrating A Reduction Of Treated Bleeding Episodes With Both Once-Weekly And Once-Monthly Mim8 Versus No Prophylaxis Treatment And Prior...
諾和諾德公佈了FRONTIER 2試驗的總體結果；通過證明每週一次和每月一次的Mim8與不進行預防治療和事先治療相比，治療的出血發作有所減少，從而實現了其共同主要終點...
Novo Nordisk Announces Headline Results From The FRONTIER 2 Trial; Achieved Its Co-Primary Endpoints By Demonstrating A Reduction Of Treated Bleeding Episodes With Both Once-Weekly And Once-Monthly Mim8 Versus No Prophylaxis Treatment And Prior Coagulation Factor Prophylaxis Treatment
諾和諾德公佈了FRONTIER 2試驗的主要結果；通過證明每週一次和每月一次的Mim8與無預防治療和先前的凝血因子預防治療相比，治療的出血發作有所減少，從而實現了其共同主要終點
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。